Key result
Combination treatment of Qiliqiangxin with an ARB, ACEI, or beta-blocker significantly enhanced the attenuation of pressure overload-induced cardiac remodeling, dysfunction, and cardiomyocyte apoptosis compared to Qiliqiangxin alone.
Why the study?
Does combining Qiliqiangxin with an ARB, ACEI, or BB improve cardiac remodeling and dysfunction compared to Qiliqiangxin alone in a mouse model of pressure overload?
Population
Adult male mice (C57B/L6) subjected to transverse aortic constriction (pressure overload) or sham operation
Comparison
Qiliqiangxin combined with an angiotensin II… vs Qiliqiangxin (QL) alone or saline
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Should not change practice; hypothesis-generating for combinations in pressure-overload models.
Does combining Qiliqiangxin with an ARB, ACEI, or BB improve cardiac remodeling and dysfunction compared to Qiliqiangxin alone in a mouse model of pressure overload?
p-value: p=<0.05
Combining Qiliqiangxin with standard antihypertensive agents (ARB, ACEI, or BB) provides synergistic benefits in attenuating pressure overload-induced cardiac hypertrophy and remodeling in a preclinical model.
Ye et al. (2015) studied Chronic pressure overload-induced cardiac hypertrophy and remodeling (n=42). Qiliqiangxin combined with olmesartan, captopril, or metoprolol vs. Qiliqiangxin alone, saline (TAC control), or sham operation was evaluated on Cardiac remodeling and dysfunction (including echocardiographic parameters, hypertrophic gene expression, and apoptosis) (p=<0.05). Combination treatment of Qiliqiangxin with an ARB, ACEI, or beta-blocker significantly enhanced the attenuation of pressure overload-induced cardiac remodeling, dysfunction, and cardiomyocyte apoptosis compared to Qiliqiangxin alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: